Inceptionr LLC Makes New $401,000 Investment in STAAR Surgical Company $STAA

Inceptionr LLC bought a new stake in shares of STAAR Surgical Company (NASDAQ:STAA) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 21,450 shares of the medical instruments supplier’s stock, valued at approximately $401,000.

Several other large investors have also recently made changes to their positions in the company. Balyasny Asset Management L.P. bought a new position in shares of STAAR Surgical during the 3rd quarter valued at approximately $48,729,000. Broadwood Capital Inc. raised its position in STAAR Surgical by 11.1% in the 4th quarter. Broadwood Capital Inc. now owns 15,019,491 shares of the medical instruments supplier’s stock worth $346,800,000 after purchasing an additional 1,500,000 shares during the period. Magnetar Financial LLC lifted its stake in STAAR Surgical by 105.3% in the fourth quarter. Magnetar Financial LLC now owns 2,472,390 shares of the medical instruments supplier’s stock worth $57,087,000 after purchasing an additional 1,268,019 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of STAAR Surgical by 112.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,076,743 shares of the medical instruments supplier’s stock valued at $47,952,000 after buying an additional 1,100,484 shares during the period. Finally, Water Island Capital LLC purchased a new position in shares of STAAR Surgical during the third quarter valued at approximately $17,689,000. 96.70% of the stock is owned by institutional investors.

STAAR Surgical Price Performance

Shares of NASDAQ STAA opened at $23.38 on Monday. STAAR Surgical Company has a 52-week low of $15.59 and a 52-week high of $35.87. The firm has a market capitalization of $1.16 billion, a price-to-earnings ratio of -54.37 and a beta of 1.23. The stock has a 50 day moving average price of $28.85 and a 200 day moving average price of $23.84. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.31 and a current ratio of 5.12.

STAAR Surgical (NASDAQ:STAA) last released its quarterly earnings data on Wednesday, May 13th. The medical instruments supplier reported $0.10 EPS for the quarter, topping the consensus estimate of $0.05 by $0.05. STAAR Surgical had a positive return on equity of 3.31% and a negative net margin of 7.24%.The company had revenue of $93.52 million for the quarter, compared to the consensus estimate of $78.72 million. During the same period last year, the business posted ($1.10) EPS. STAAR Surgical’s quarterly revenue was up 119.6% on a year-over-year basis. Sell-side analysts expect that STAAR Surgical Company will post 0.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

STAA has been the subject of a number of research analyst reports. Stifel Nicolaus raised their price target on STAAR Surgical from $18.00 to $31.00 and gave the stock a “hold” rating in a research note on Thursday, May 14th. Piper Sandler increased their target price on STAAR Surgical from $16.00 to $33.00 and gave the stock a “neutral” rating in a research note on Thursday, May 14th. Wedbush reiterated an “outperform” rating and set a $40.00 target price on shares of STAAR Surgical in a research report on Wednesday, July 22nd. Mizuho lifted their target price on STAAR Surgical from $22.00 to $27.00 and gave the stock a “neutral” rating in a research report on Thursday, May 14th. Finally, Wall Street Zen raised shares of STAAR Surgical from a “hold” rating to a “buy” rating in a research note on Sunday, July 5th. Three equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $27.81.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.